ImmuPharma PLC: Encouraging Final Phase IIb Results Seen With LUPUZOR™ In Systemic Lupus Erythematosus
by admin on December 21st, 2009
ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company is pleased to announce the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE)…
Tagged as:
